Your browser doesn't support javascript.
loading
Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL.
Zhang, Jiqin; Hu, Yongxian; Yang, Jiaxuan; Li, Wei; Zhang, Mingming; Wang, Qingcan; Zhang, Linjie; Wei, Guoqing; Tian, Yue; Zhao, Kui; Chen, Ang; Tan, Binghe; Cui, Jiazhen; Li, Deqi; Li, Yi; Qi, Yalei; Wang, Dongrui; Wu, Yuxuan; Li, Dali; Du, Bing; Liu, Mingyao; Huang, He.
Afiliación
  • Zhang J; Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China. zjqjeremy@163.com.
  • Hu Y; Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Yang J; Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, China.
  • Li W; Institute of Hematology, Zhejiang University, Hangzhou, China.
  • Zhang M; Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China.
  • Wang Q; Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China.
  • Zhang L; BRL Medicine, Inc., Shanghai, China.
  • Wei G; Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Tian Y; Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, China.
  • Zhao K; Institute of Hematology, Zhejiang University, Hangzhou, China.
  • Chen A; Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China.
  • Tan B; BRL Medicine, Inc., Shanghai, China.
  • Cui J; Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China.
  • Li D; Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Li Y; Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, China.
  • Qi Y; Institute of Hematology, Zhejiang University, Hangzhou, China.
  • Wang D; Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China.
  • Wu Y; Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China.
  • Li D; PETCT Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
  • Du B; Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China.
  • Liu M; BRL Medicine, Inc., Shanghai, China.
  • Huang H; Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China.
Nature ; 609(7926): 369-374, 2022 09.
Article en En | MEDLINE | ID: mdl-36045296
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Inmunoterapia Adoptiva / Linfoma de Células B / Receptores Quiméricos de Antígenos Tipo de estudio: Guideline Idioma: En Revista: Nature Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Inmunoterapia Adoptiva / Linfoma de Células B / Receptores Quiméricos de Antígenos Tipo de estudio: Guideline Idioma: En Revista: Nature Año: 2022 Tipo del documento: Article